Psychotropic Medication Monitoring and Documentation Deficiencies
Summary
The facility failed to ensure seven sampled residents were free from unnecessary psychotropic medication use and failed to document required monitoring and nonpharmacological interventions associated with those medications. The report states that the facility did not ensure orthostatic blood pressure monitoring for residents receiving antipsychotic medications, did not consistently document behavior monitoring tied to the stated indications for psychotropic drugs, and did not document nonpharmacological interventions or their effectiveness when behaviors were observed. For one resident with diagnoses including anxiety disorder and bipolar disorder, olanzapine was ordered for mood swings, and hydroxyzine and Ativan were ordered for anxiety manifested by uncontrolled crying causing physical exhaustion. The record showed frequent episodes of mood swings and crying, but there was no documentation of orthostatic hypotension monitoring for olanzapine and no documentation of nonpharmacological interventions implemented for the observed behaviors related to olanzapine, hydroxyzine, or Ativan. Staff interviews confirmed the absence of those documented interventions and monitoring. For another resident with moderately impaired cognition and diagnoses including non-Alzheimer's dementia and major depressive disorder, aripiprazole was ordered for schizophrenia manifested by resistive to care, Cymbalta was ordered for schizoaffective depressive type manifested by verbally feeling depressed, and temazepam was ordered for insomnia. The record did not show orthostatic hypotension monitoring for aripiprazole, and staff confirmed the resident did not have the diagnoses listed for aripiprazole and Cymbalta. The record also showed temazepam administration on multiple dates, but monitoring of hours of sleep was only documented for an earlier period and not after that point. Additional residents had similar documentation problems. One resident receiving Cymbalta had pain used as the behavior manifestation, but the record did not show physician justification for using pain in that way and the monthly behavior summary did not match the pain episodes documented in the MAR. Another resident receiving Remeron had meal intake documented in ranges that did not allow staff to identify when intake was less than 50%, and the monthly behavior summary showed zero episodes despite documented poor intake. Other residents receiving lorazepam, Remeron, quetiapine, and sertraline also lacked documentation of required nonpharmacological interventions, side-effect monitoring, orthostatic blood pressure monitoring, or accurate behavior summaries as described in the report.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.